<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.28996/2618-9801-2020-3-396-405</article-id><article-id custom-type="elpub" pub-id-type="custom">nid-221</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАБЛЮДЕНИЯ ИЗ ПРАКТИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>Атипическая аденома околощитовидной железы у пациентки с хронической болезнью почек. Клиническое наблюдение и обзор литературы</article-title><trans-title-group xml:lang="en"><trans-title>Atypical parathyroid adenoma in patient with chronic kidney disease. Case report and literature review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ветчинникова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Vetchinnikova</surname><given-names>O. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Прокопенко</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Prokopenko</surname><given-names>E. I.</given-names></name></name-alternatives><email xlink:type="simple">renalnephron@gmail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронкова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Voronkova</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондаренко</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarenko</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ МО Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M.F. Vladimirsky Moscow Regional Clinical and Research Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>07</month><year>2024</year></pub-date><volume>22</volume><issue>3</issue><fpage>396</fpage><lpage>405</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ветчинникова О.Н., Прокопенко Е.И., Воронкова И.А., Бондаренко Е.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ветчинникова О.Н., Прокопенко Е.И., Воронкова И.А., Бондаренко Е.В.</copyright-holder><copyright-holder xml:lang="en">Vetchinnikova O.N., Prokopenko E.I., Voronkova I.A., Bondarenko E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/221">https://journal.nephro.ru/jour/article/view/221</self-uri><abstract><p>Атипическая аденома околощитовидных желез (ОЩЖ) - редкая причина первичного гиперпаратиреоза (ГПТ), диагноз устанавливается при морфологическом исследовании удаленной железы. В опубликованной литературе не обнаружено ни одного описания первичного ГПТ, вызванного атипической аденомой ОЩЖ, при хронической болезни почек (ХБП). Представляем клиническое наблюдение молодой женщины, у которой заболевание дебютировало гипертоническим кризом (АД 210/130 мм рт.ст.), протеинурией нефротического уровня и при биохимическом исследовании крови креатинин составил 169 мкмоль/л (расчетная скорость клубочковой фильтрации (рСКФ) 37 мл/мин), при нефробиопсии - фокальный глобальный и сегментарный гломерулосклероз. Диагностирована ХБП 3 стадии, рекомендована нефропротективная терапия. Результаты обследования через 8 лет (в связи с планированием беременности): креатинин 156 мкмоль/л (рСКФ 40 мл/мин), ионизированный кальций 1,37 ммоль/л, фосфор 1,01 ммоль/л, паратиреоидный гормон (ПТГ) 91 пг/мл, ультразвуковое исследование (УЗИ) передней поверхности шеи: в проекции ОЩЖ дополнительные образования отсутствуют. Еще через год во время беременности креатинин крови 137 мкмоль/л, скорректированный на сывороточный альбумин общий кальций 2,89 ммоль/л, ПТГ 47 пг/мл. После успешных родов прогрессирование ХБП и перевод на лечение перитонеальным диализом. Регистрировались ПТГ 1613 пг/мл, общий кальций 2,92-2,67 ммоль/л, фосфор 2,12 ммоль/л, активность щелочной фосфатазы 857 ед/л (норма 3-258); УЗИ передней поверхности шеи: образование правой нижней ОЩЖ (26×15×13 мм). Выполнена селективная паратиреоидэктомия справа. Морфологическое исследование: опухолевый узел из главных клеток с трабекулярными и периваскулярными розеткоподобными структурами; толстая фиброзная капсула с очагами опухолевых комплексов; повышенная митотическая активность. При иммуногистохимическом исследовании диффузная интенсивная экспрессия ПТГ, индекс пролиферации Ki-67 10%. Заключение: атипическая аденома ОЩЖ (рТisNx в соответствии с American Joint Committee on Cancer, 2017). В послеоперационном периоде затяжной синдром «голодной кости». Представлена краткая клиническая, биохимическая и морфологическая характеристика атипической аденомы ОЩЖ.</p></abstract><trans-abstract xml:lang="en"><p>Atypical parathyroid adenoma is a rare cause of primary hyperparathyroidism (HPT). It can be diagnosed by morphological examination of the removed gland. In the published literature, We could not find any description of the primary HPT caused by atypical parathyroid adenoma in chronic kidney disease (CKD) in literature. Here we present a clinical observation of a young woman whose disease debuted with a hypertension (BP 210/130 mm Hg), proteinuria and high blood creatinine level (169 μmol/l, eGFR - 37 ml/min). Nephrobiopsy revealed focal global and segmental glomerulosclerosis. CKD stage 3 has been diagnosed, nephroprotective therapy was recommended. Blood biochemical examination after 8 years (before pregnancy): creatinine level - 156 μmol/l (eGFR 40 ml/min), ionized calcium and phosphorus 1.37 and 1.01 mmol/l, parathyroid hormone (PTH) 91 pg/ml. Neck ultrasound revealed no additional mass in the projection of the parathyroid glands (PG). After another year during pregnancy, creatinine was 137 μmol/l, total calcium corrected for serum albumin - 2.89 mmol/l, PTH - 47 pg/ml. CKD progressed after successful delivery, patient started of peritoneal dialysis treatment. PTH was 1613 pg/ml, calcium - 2.92-2.67 mmol/l, phosphorus - 2.12 mmol/l, alkaline phosphatase activity - 857 U/l (normal 3-258). Neck ultrasound a mass (26×15×13 mm) in the right lower PG. Selective parathyroidectomy was performed. Morphological study: a tumor node from the main cells with trabecular and perivascular rosette-like structures; a thick fibrous capsule with foci of tumor complexes; increased mitotic activity. Diffuse intense expression of PTH and proliferation index Ki-67=10% found in the immunohystochemical study. Conclusion: atypical parathyroid adenoma (pTisNx in accordance with American Joint Committee on Cancer, 2017). The protracted «hunger bone» syndrome was observed in the postoperative period. A brief clinical, biochemical and morphological characteristics of the atypical parathyroid adenoma are presented.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>первичный гиперпаратиреоз</kwd><kwd>атипическая аденома околощитовидной железы</kwd><kwd>синдром «голодной кости»</kwd><kwd>chronic kidney disease</kwd><kwd>primary hyperparathyroidism</kwd><kwd>atypical parathyroid adenoma</kwd><kwd>«hungry bone» syndrome</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">DeLellis R., Lloyd R., Heitz P., Eng C. Pathology and Genetics. Tumors of Endocrine Organs. WHO Classification of Tumours. Lyon, France. IARC Press, 2004.</mixed-citation><mixed-citation xml:lang="en">DeLellis R., Lloyd R., Heitz P., Eng C. Pathology and Genetics. Tumors of Endocrine Organs. WHO Classification of Tumours. Lyon, France. IARC Press, 2004.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rosai J., DeLellis R., Carcangiu M. et al. Parathyroid adenoma and variants. In Tumors of the Thyroid and Parathyroid Glands. Armed Forces Institute of Pathology; Atlas of Tumor Pathology 4th Series, 2014: 513-542.</mixed-citation><mixed-citation xml:lang="en">Rosai J., DeLellis R., Carcangiu M. et al. Parathyroid adenoma and variants. In Tumors of the Thyroid and Parathyroid Glands. Armed Forces Institute of Pathology; Atlas of Tumor Pathology 4th Series, 2014: 513-542.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">DeLellis R., Larsson C., Arnold A. et al. Tumors of the parathyroid glands. In WHO Classification of Tumors of Endocrine Organs, 4th ed., Eds R. Lloyd, R. Osamura, G. Kloppel, J. Rosai. Lyon, France: IARC Press 2017: 145-159.</mixed-citation><mixed-citation xml:lang="en">DeLellis R., Larsson C., Arnold A. et al. Tumors of the parathyroid glands. In WHO Classification of Tumors of Endocrine Organs, 4th ed., Eds R. Lloyd, R. Osamura, G. Kloppel, J. Rosai. Lyon, France: IARC Press 2017: 145-159.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Landry C.S., Wang T.S., Asare E.A. Parathyroid. In: AJCC Cancer Staging Manual. Springer; 2017: 903-910. doi: 10.1007/978-3-319-40618-3-75.</mixed-citation><mixed-citation xml:lang="en">Landry C.S., Wang T.S., Asare E.A. Parathyroid. In: AJCC Cancer Staging Manual. Springer; 2017: 903-910. doi: 10.1007/978-3-319-40618-3-75.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gospodarowicz M.K., Brierley J.D., Wittekind C. (ed.). TNM classification of malignant tumors. John Wiley &amp; Sons, 2017. doi: 10.1016/S1470-2045(17)30438-2.</mixed-citation><mixed-citation xml:lang="en">Gospodarowicz M.K., Brierley J.D., Wittekind C. (ed.). TNM classification of malignant tumors. John Wiley &amp; Sons, 2017. doi: 10.1016/S1470-2045(17)30438-2.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Christakis I., Busaidy N.L., Cote G.J. et al. Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinicopathologic challenge. The MD Anderson case series and review of the literature. Int J Surg. 2016; 31: 10-16. doi: 10.1016/j.ijsu.2016.05.035.</mixed-citation><mixed-citation xml:lang="en">Christakis I., Busaidy N.L., Cote G.J. et al. Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinicopathologic challenge. The MD Anderson case series and review of the literature. Int J Surg. 2016; 31: 10-16. doi: 10.1016/j.ijsu.2016.05.035.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ramaswamy A.S., Vijitha T., Kumarguru B.N., Mahalingashetti PB. Atypical parathyroid adenoma. Indian J Pathol Microbiol 2017; 60: 99-101.</mixed-citation><mixed-citation xml:lang="en">Ramaswamy A.S., Vijitha T., Kumarguru B.N., Mahalingashetti PB. Atypical parathyroid adenoma. Indian J Pathol Microbiol 2017; 60: 99-101.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dobrinja C., Santandrea G., Giacca M. et al. Effectiveness of Intraoperative Parathyroid Monitoring (ioPTH) in predicting a multiglandular or malignant parathyroid disease. Int J Surg. 2017; 41 Suppl 1: S26-S33. doi: 10.1016/j.ijsu.2017.02.063.</mixed-citation><mixed-citation xml:lang="en">Dobrinja C., Santandrea G., Giacca M. et al. Effectiveness of Intraoperative Parathyroid Monitoring (ioPTH) in predicting a multiglandular or malignant parathyroid disease. Int J Surg. 2017; 41 Suppl 1: S26-S33. doi: 10.1016/j.ijsu.2017.02.063.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Saponaro F., Cetani F., Repaci A. et al. Clinical presentation and management of patients with primary hyperparathyroidism in Italy. Journal of Endocrinological Investigation 2018; 41: 1339-1348. Doi: 10.1007/s40618-018-0879-z</mixed-citation><mixed-citation xml:lang="en">Saponaro F., Cetani F., Repaci A. et al. Clinical presentation and management of patients with primary hyperparathyroidism in Italy. Journal of Endocrinological Investigation 2018; 41: 1339-1348. Doi: 10.1007/s40618-018-0879-z</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Grube M., Bech J.N., Pedersen E.B. Primary hyperparathyroidism as a cause of chronic renal failure. Ugeskr Laeger 2012; 174(8): 502-503.</mixed-citation><mixed-citation xml:lang="en">Grube M., Bech J.N., Pedersen E.B. Primary hyperparathyroidism as a cause of chronic renal failure. Ugeskr Laeger 2012; 174(8): 502-503.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ветчинннкова О.Н., Денисова Л.Б., Гаганов Л.Е. Трудности дифференциальной диагностики тяжелого гиперпаратиреоза, выявленного на стадии терминальной почечной недостаточности (Клиническое наблюдение). Нефрология и диализ 2015; 17 (1): 78-88.</mixed-citation><mixed-citation xml:lang="en">Ветчинннкова О.Н., Денисова Л.Б., Гаганов Л.Е. Трудности дифференциальной диагностики тяжелого гиперпаратиреоза, выявленного на стадии терминальной почечной недостаточности (Клиническое наблюдение). Нефрология и диализ 2015; 17 (1): 78-88.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ветчинннкова О.Н., Бритвин Т.А., Гулимова С.Ю. Хроническая болезнь почек и гиперпаратиреоз: первичный и/или вторичный? Клиническая нефрология 2016; 1:33-37.</mixed-citation><mixed-citation xml:lang="en">Ветчинннкова О.Н., Бритвин Т.А., Гулимова С.Ю. Хроническая болезнь почек и гиперпаратиреоз: первичный и/или вторичный? Клиническая нефрология 2016; 1:33-37.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dochez V., Ducarme G. Primary hyperparathyroidism during pregnancy. Arch Gynecol Obstet 2015; 291: 259-263. DOI: 10.1007/s00404-014-3526-8</mixed-citation><mixed-citation xml:lang="en">Dochez V., Ducarme G. Primary hyperparathyroidism during pregnancy. Arch Gynecol Obstet 2015; 291: 259-263. DOI: 10.1007/s00404-014-3526-8</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Кижватов С.И., Кудлай И.С., Межинская Е.М. Первичный гиперпаратиреоз у беременных (клинические наблюдения). Научный вестник здравоохранения Кубани 2017; 5 (53): 17-24.</mixed-citation><mixed-citation xml:lang="en">Кижватов С.И., Кудлай И.С., Межинская Е.М. Первичный гиперпаратиреоз у беременных (клинические наблюдения). Научный вестник здравоохранения Кубани 2017; 5 (53): 17-24.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Eastell R., Arnold A., Brandi M.L. et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94 (2): 340-350.</mixed-citation><mixed-citation xml:lang="en">Eastell R., Arnold A., Brandi M.L. et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94 (2): 340-350.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94 (2): 335-339.</mixed-citation><mixed-citation xml:lang="en">Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94 (2): 335-339.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kovacs C.S. Calcium and bone metabolism disorders during pregnancy and lactation. Endocrinology and Metabolism Clinics of North America 2011; 40: 795-826. doi:10.1016/j.ecl.2011.08.002</mixed-citation><mixed-citation xml:lang="en">Kovacs C.S. Calcium and bone metabolism disorders during pregnancy and lactation. Endocrinology and Metabolism Clinics of North America 2011; 40: 795-826. doi:10.1016/j.ecl.2011.08.002</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ветчинникова О.Н., Никольская И.Г., Иванова М.Ю. Особенности костного обмена у беременных с хронической болезнью почек. Нефрология и диализ 2018; 2: 202-211. DOI: 10.28996/2618-9801-2018-2-202-211</mixed-citation><mixed-citation xml:lang="en">Ветчинникова О.Н., Никольская И.Г., Иванова М.Ю. Особенности костного обмена у беременных с хронической болезнью почек. Нефрология и диализ 2018; 2: 202-211. DOI: 10.28996/2618-9801-2018-2-202-211</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Cunningham J., Locatelli F., Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913-921.doi: 10.2215/CJN.06040710</mixed-citation><mixed-citation xml:lang="en">Cunningham J., Locatelli F., Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression and therapeutic options. Clin J Am Soc Nephrol 2011; 6: 913-921.doi: 10.2215/CJN.06040710</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jamal S.A., Miller P.D. Secondary and Tertiary Hyperparathyroidism. Journal of Clinical Densitometry: Assessment of Skeletal Health 2013; 16(1): 64-68. http://dx.doi.org/10.1016/j.jocd.2012.11.012</mixed-citation><mixed-citation xml:lang="en">Jamal S.A., Miller P.D. Secondary and Tertiary Hyperparathyroidism. Journal of Clinical Densitometry: Assessment of Skeletal Health 2013; 16(1): 64-68. http://dx.doi.org/10.1016/j.jocd.2012.11.012</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ruda J.M., Hollenbeak C.S., Stack B.C.Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132: 359-372.</mixed-citation><mixed-citation xml:lang="en">Ruda J.M., Hollenbeak C.S., Stack B.C.Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132: 359-372.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lunn M.R., Mendoza J.M., Pasche L.J. et al. Hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary? Nephrol Dial Transplant Plus 2010; 3: 366-371. doi: 10.1093/ndtplus/sfq077</mixed-citation><mixed-citation xml:lang="en">Lunn M.R., Mendoza J.M., Pasche L.J. et al. Hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary? Nephrol Dial Transplant Plus 2010; 3: 366-371. doi: 10.1093/ndtplus/sfq077</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cetani F., Marcocci C., Torregrossa L. Pardi E. Atypical parathyroid adenomas: Challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer 2019; 26 (7): R441-R464. DOI: 10.1530/ERC-19-0135</mixed-citation><mixed-citation xml:lang="en">Cetani F., Marcocci C., Torregrossa L. Pardi E. Atypical parathyroid adenomas: Challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer 2019; 26 (7): R441-R464. DOI: 10.1530/ERC-19-0135</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Marx S.J., Goltzman D. Evolution of our understanding of the hyperparathyroid syndromes: a historical perspective. Journal of Bone and Mineral Research 2019; 34: 22-37. Doi: 10.1002/ jbmr.3650</mixed-citation><mixed-citation xml:lang="en">Marx S.J., Goltzman D. Evolution of our understanding of the hyperparathyroid syndromes: a historical perspective. Journal of Bone and Mineral Research 2019; 34: 22-37. Doi: 10.1002/ jbmr.3650</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal A., Pradhan R., Kumari N. et al. Molecular characteristics of large parathyroid adenomas. World J Surg 2015. DOI 10.1007/s00268-015-3380-2</mixed-citation><mixed-citation xml:lang="en">Agarwal A., Pradhan R., Kumari N. et al. Molecular characteristics of large parathyroid adenomas. World J Surg 2015. DOI 10.1007/s00268-015-3380-2</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hosny Mohammed K., Siddiqui M.T., Willis B.C. et al. Parafibromin, APC, and MIB-1 are useful markers for distinguishing parathyroid carcinomas from adenomas. Applied Immunohistochemistry and Molecular Morphology 2017; 25: 731-735. Doi: 10.1097/PAI.0000000000000378</mixed-citation><mixed-citation xml:lang="en">Hosny Mohammed K., Siddiqui M.T., Willis B.C. et al. Parafibromin, APC, and MIB-1 are useful markers for distinguishing parathyroid carcinomas from adenomas. Applied Immunohistochemistry and Molecular Morphology 2017; 25: 731-735. Doi: 10.1097/PAI.0000000000000378</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ozolins A., Narbuts Z., Vanags A. et al. Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism. Langenbeck’s Archives of Surgery 2016; 401: 943-951. Doi: 10.1007/s00423- 015-1361-4</mixed-citation><mixed-citation xml:lang="en">Ozolins A., Narbuts Z., Vanags A. et al. Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism. Langenbeck’s Archives of Surgery 2016; 401: 943-951. Doi: 10.1007/s00423- 015-1361-4</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kumari N., Chaudhary N., Pradhan R. et al. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms. Endocr Pathol. 2016; 27 (2): 87-96. doi: 10.1007/s12022-016-9426-7.</mixed-citation><mixed-citation xml:lang="en">Kumari N., Chaudhary N., Pradhan R. et al. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms. Endocr Pathol. 2016; 27 (2): 87-96. doi: 10.1007/s12022-016-9426-7.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Y., Liao Q., Cao S. et al. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. Endocrine 2016; 54: 612-619. doi: 10.1007/s12020-016-0997-3</mixed-citation><mixed-citation xml:lang="en">Hu Y., Liao Q., Cao S. et al. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. Endocrine 2016; 54: 612-619. doi: 10.1007/s12020-016-0997-3</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kruijff S., Sidhu S.B., Sywak M.S. et al. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2014; 21 (2): 426-433. doi: 10.1245/s10434-013-3288-8.</mixed-citation><mixed-citation xml:lang="en">Kruijff S., Sidhu S.B., Sywak M.S. et al. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2014; 21 (2): 426-433. doi: 10.1245/s10434-013-3288-8.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gill A.J., Lim G., Cheung V.K.Y. et al. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. Am J Surg Pathol. 2019; 43(1): 35-46. doi: 10.1097/PAS.0000000000001017.</mixed-citation><mixed-citation xml:lang="en">Gill A.J., Lim G., Cheung V.K.Y. et al. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. Am J Surg Pathol. 2019; 43(1): 35-46. doi: 10.1097/PAS.0000000000001017.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ryhänen E. M., Leijon H., Metso S. et al. A nationwide study on parathyroid carcinoma. Acta Oncolgica 2017; 7: 991-1003. http://dx.doi.org/10.1080/0284186X.2017.1306103</mixed-citation><mixed-citation xml:lang="en">Ryhänen E. M., Leijon H., Metso S. et al. A nationwide study on parathyroid carcinoma. Acta Oncolgica 2017; 7: 991-1003. http://dx.doi.org/10.1080/0284186X.2017.1306103</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Florakis D., Karakozis S., Tseleni-Balafouta S., Makras P. Lessons Learned From the Management of Hungry Bone Syndrome Following the Removal of an Atypical Parathyroid Adenoma. J Musculoskelet Neuronal Interact 2019; 19 (3): 379-384.</mixed-citation><mixed-citation xml:lang="en">Florakis D., Karakozis S., Tseleni-Balafouta S., Makras P. Lessons Learned From the Management of Hungry Bone Syndrome Following the Removal of an Atypical Parathyroid Adenoma. J Musculoskelet Neuronal Interact 2019; 19 (3): 379-384.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Juarez-Leon O.A., Gomez-Samano M.A., Cuevas-Ramos D. et al. Atypical Parathyroid Adenoma Complicated With Protracted Hungry Bone Syndrome After Surgery: A Case Report and Literature Review. Case Rep Endocrinol 2015; Article ID 757951, 8 pages. doi:10.1155/2015/757951</mixed-citation><mixed-citation xml:lang="en">Juarez-Leon O.A., Gomez-Samano M.A., Cuevas-Ramos D. et al. Atypical Parathyroid Adenoma Complicated With Protracted Hungry Bone Syndrome After Surgery: A Case Report and Literature Review. Case Rep Endocrinol 2015; Article ID 757951, 8 pages. doi:10.1155/2015/757951</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Massfelder T., Parekh N., Endlich K. et al. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized. Br J Pharmacol 1996; 118: 1995-2000.</mixed-citation><mixed-citation xml:lang="en">Massfelder T., Parekh N., Endlich K. et al. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized. Br J Pharmacol 1996; 118: 1995-2000.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Trizna W., Edwards R.M. Relaxation of renal arterioles by parathyroid hormone and parathyroid hormone-related protein. Pharmacology 1991; 42: 91-96.</mixed-citation><mixed-citation xml:lang="en">Trizna W., Edwards R.M. Relaxation of renal arterioles by parathyroid hormone and parathyroid hormone-related protein. Pharmacology 1991; 42: 91-96.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Schwarz A., Rustien G., Merkel S. et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22: 584-591. doi: 10.1093/ndt/gfl583</mixed-citation><mixed-citation xml:lang="en">Schwarz A., Rustien G., Merkel S. et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22: 584-591. doi: 10.1093/ndt/gfl583</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
